Wire · opportunities
Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
Sebela Pharmaceuticals announced positive Phase 3 trial results for tegoprazan demonstrating significant improvement in heartburn and regurgitation symptoms in non-erosive reflux disease (NERD) patients, with sustained effect over 20 weeks. The data were presented at the American College of Gastroenterology 2026 meeting and recognized with an ACG Presidential Award.
This Wire brief sits within Fusion42's coverage of Health: Medtech.
◆ ◆ The Wire takeaway
You just saw a new standard setting for rapid symptom relief in reflux disease. If you work in gastroenterology treatments, tegoprazan's success opens a door for innovation in non-erosive reflux therapies with a fast-acting profile.
◆ Coverage
1 source · 11 Oct 2026
◆ Related on Wire
◆ Topics